Natera Announces Senior Leadership Changes
Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.Solomon Moshkevich has been...
Neutral
or
Natera Inc News & Analysis
-
-
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera for Breast Cancer Patients in the Neoadjuvant Setting
Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that...
-
Natera Pruces 4.55M Share Follow-on Offering at $55/sh
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a...
-
Natera Announces Proposed $250M Follow-on Share Offering
Natera, Inc. (Nasdaq: NTRA) today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the...
-
Natera's Prospera Lung Transplant Assessment Test Granted Medicare Coverage
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA)...
-
Piper Sandler maintains Natera Inc at 'overweight' with a price target of $80.00
An analyst from Piper Sandler maintained Natera Inc (NASDAQ: NTRA) at 'overweight' with a price target of $80.00 from a prior price target of $70.00. Prior to this rating, Natera Inc had...
-
Morgan Stanley maintains Natera Inc at 'overweight' with a price target of $70.00
An analyst from Morgan Stanley maintained Natera Inc (NASDAQ: NTRA) at 'overweight' with a price target of $70.00 from a prior price target of $72.00. Prior to this rating, Natera Inc...
-
Morgan Stanley maintains Natera Inc at 'overweight' with a price target of $70.00
An analyst from Morgan Stanley maintained Natera Inc (NASDAQ: NTRA) at 'overweight' with a price target of $70.00 from a prior price target of $72.00. Prior to this rating, Natera Inc...
-
Baird maintains Natera Inc at 'outperform' with a price target of $68.00
An analyst from Baird maintained Natera Inc (NASDAQ: NTRA) at 'outperform' with a price target of $68.00 from a prior price target of $66.00. Prior to this rating, Natera Inc had 14 buy...
-
Natera Inc earnings beat by $0.12, revenue topped estimates
Investing.com - Natera Inc (NASDAQ: NTRA) reported second quarter EPS of $-0.97, $0.12 better than the analyst estimate of $-1.09. Revenue for the quarter came in at $261.4M versus the...
-
Natera Files Patent Infringement Case against Neogenomics
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc....
-
Goldman Sachs maintains Natera Inc at 'buy' with a price target of $60.00
An analyst from Goldman Sachs maintained Natera Inc (NASDAQ: NTRA) at 'buy' with a price target of $60.00 from a prior price target of $70.00. Prior to this rating, Natera Inc had 14 buy...
-
Goldman Sachs maintains Natera Inc at 'buy' with a price target of $60.00
An analyst from Goldman Sachs maintained Natera Inc (NASDAQ: NTRA) at 'buy' with a price target of $60.00 from a prior price target of $70.00. Prior to this rating, Natera Inc had 13 buy...
-
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
CareDx, Inc. (Nasdaq: NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for...
-
Natera Announces Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware issued a decision in favor of Natera...
-
TD Cowen maintains Natera Inc at 'outperform' with a price target of $82.00
An analyst from TD Cowen maintained Natera Inc (NASDAQ: NTRA) at 'outperform' with a price target of $82.00. Prior to this rating, Natera Inc had 13 buy ratings, 0 hold ratings, and 1...
-
InVitae to Appeal Trial Verdict Against Natera
Invitae (NYSE:NVTA) (NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District...
-
Jury Rules in Favor of Natera , Awards $19.35M in Past Damages; Finds all Asserted Patents Valid and Infringed by ArcherDX/Invitae
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in...
-
Baird maintains Natera Inc at 'outperform' with a price target of $66.00
An analyst from Baird maintained Natera Inc (NASDAQ: NTRA) at '' 'outperform' and a price target of $66.00 from a prior price target of $65.00. Prior to this rating, Natera Inc had 14 buy...
-
Credit Suisse maintains Natera Inc at 'outperform' with a price target of $70.00
An analyst from Credit Suisse maintained Natera Inc (NASDAQ: NTRA) at '' 'outperform' and a price target of $70.00 from a prior price target of $65.00. Prior to this rating, Natera Inc had...
-
Natera Inc earnings missed by $0.07, revenue topped estimates
Investing.com - Natera Inc (NASDAQ: NTRA) reported first quarter EPS of $-1.23, $0.07 worse than the analyst estimate of $-1.16. Revenue for the quarter came in at $241.8M versus the...
-
UBS new coverage Natera Inc Buy, PT $76.00
An UBS analyst initiated new coverage Natera Inc (NASDAQ: NTRA) Buy rating and a price target of $76.00. Prior to this rating, Natera Inc had 14 buy ratings, 0 hold ratings, and 1 sell...
-
Canaccord Genuity maintains Natera Inc at Buy, PT $87.00
A Canaccord Genuity analyst maintained Natera Inc (NASDAQ: NTRA) at Buy and a price target of $87.00 from a prior price target of $97.00. Prior to this rating, Natera Inc had 13 buy...
-
Natera Reports New Publication Demonstrates Utility of Natera’s Signatera Test in Melanoma
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized...
-
Natera Announces Commercial Payor Coverage for Signatera
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera,...
-
Natera Tops Q4 EPS by 6c
Natera (NASDAQ:NTRA) reported Q4 EPS of ($1.37), $0.06 better than the analyst estimate of ($1.43). Revenue for the quarter came in at $217.3 million versus the consensus estimate of $215.57...
-
Natera Inc earnings beat by $0.06, revenue topped estimates
Investing.com - Natera Inc (NASDAQ: NTRA) reported fourth quarter EPS of $-1.37, $0.06 better than the analyst estimate of $-1.43. Revenue for the quarter came in at $217.3M versus the...
-
Natera Appoints Ruth E. Williams-Brinkley to its Board
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors.Williams-Brinkley...
-
Natera Inc Earnings, Revenue beat In Q3
Investing.com - Natera Inc reported on Tuesday third quarter {{erl-955853||earnings that beat analysts' forecasts and revenue that topped expectations. Natera Inc announced earnings per...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.00%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Technology, Basic Materials and Financials sectors propelled shares higher. At the close in NYSE, the...
-
Natera Plunges After Hindenburg Short Report
By Sam Boughedda Investing.com -- Clinical genetic testing company Natera Inc (NASDAQ:NTRA) is down 48% after Hindenburg Research released a short report on the company titled "Natera:...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.17%
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Utilities, Consumer Services and Telecoms sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
